fexapotide triflutate

caspase and TNF signaling pathway activator used to treat benign prostatic hyperplasia (BPH)

Also Known As:

L-Leucine, L-isoleucyl-L-alpha-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L-alpha-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl-, 2,2,2-trifluoroacetate (1:5)

Networked: 5 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shore, Neal: 3 articles (12/2020 - 05/2018)
2.	Tutrone, Ronald: 3 articles (12/2020 - 05/2018)
3.	Bailen, James: 2 articles (12/2020 - 05/2018)
4.	Bidair, Mohamed: 2 articles (12/2020 - 05/2018)
5.	Freedman, Sheldon: 2 articles (12/2020 - 05/2018)
6.	Goldberg, Kenneth: 2 articles (12/2020 - 05/2018)
7.	Hay, Alan: 2 articles (12/2020 - 05/2018)
8.	Kalota, Susan: 2 articles (12/2020 - 05/2018)
9.	Levin, Richard: 2 articles (12/2020 - 05/2018)
10.	Hay, Alan R: 1 article (05/2022)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 12/01/2020 - "This study was undertaken to determine the safety and efficacy of fexapotide triflutate (FT) 2.5 mg and 15 mg for the treatment of Grade Group 1 prostate cancer. " 01/01/2019 - "Fexapotide triflutate (FT) has been shown in human clinical trials to be a well-tolerated pharmaco-ablative agent with therapeutic benefit in patients with prostate enlargement and low-grade prostate cancer. " 12/01/2020 - "Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results."
2.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 05/01/2018 - "These studies were undertaken to determine if fexapotide triflutate 2.5 mg transrectal injectable (FT) has significant long-term (LT) safety and efficacy for the treatment of benign prostatic hyperplasia (BPH). " 01/01/2019 - "Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia."
3.	Lower Urinary Tract Symptoms 01/01/2019 - "Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia." 05/13/2022 - "To assess the price range in which fexapotide triflutate (FT), a novel injectable, is cost-effective relative to current oral pharmacotherapy (5 α-reductase inhibitor, α-blocker, 5 α-reductase inhibitor and α-blocker combination therapy) as initial therapy followed by surgery for moderate-to-severe benign prostate hyperplasia patients with lower urinary tract symptoms (BPH-LUTS). "
4.	Hyperplasia 05/13/2022 - "Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis." 05/13/2022 - "To assess the price range in which fexapotide triflutate (FT), a novel injectable, is cost-effective relative to current oral pharmacotherapy (5 α-reductase inhibitor, α-blocker, 5 α-reductase inhibitor and α-blocker combination therapy) as initial therapy followed by surgery for moderate-to-severe benign prostate hyperplasia patients with lower urinary tract symptoms (BPH-LUTS). "

Related Drugs and Biologics

1.	Oxidoreductases (Dehydrogenase)

Related Therapies and Procedures

1.	Injections
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)